Clinical Outcome after Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Central Retinal Vein Occlusion

Ophthalmic Research

Volumn 54, Issue 3, 2015, Pages 150-156

  Pfau, Maximilian ^a   Fassnacht Riederle, Heidi ^a   Becker, Matthias D ^a,d   Graf, Nicole ^c   Michels, Stephan ^a,b  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Graf Biostatistics   (Switzerland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aflibercept; Central retinal vein occlusion; Ranibizumab; Switching

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE EXAMINATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA; RETINAL VOLUME; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84942683494     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000439223     Document Type: Article

References (25)

1. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl J Med 1994;331:1480-1487.
3. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, et al: Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-1650.
4. Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, et al: Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009;116:2158-2164.
5. Noma H, Funatsu H, Mimura T, Harino S, Hori S: Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 2010;20:402-409.
6. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.e1.
7. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, et al: Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014;121:202-208.
8. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al: Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121:209-219.
9. Eghoj MS, Sorensen TL: Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012;96:21-23.
10. Forooghian F, Chew EY, Meyerle CB, Cukras C, Wong WT: Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol 2011;89:e206-e207.
11. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
12. Koss MJ, Pfister M, Koch FH: Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol 2011;2011:459251.
13. Meyer CH, Krohne TU, Holz FG: Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31:1877-1884.
14. Stewart MW, Rosenfeld PJ: Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-668.
15. Stewart MW: Predicted biologic activity of intravitreal bevacizumab. Retina 2007;27:1196-1200.
16. Yang LP, McKeage K: Intravitreal aflibercept (Eylea®): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. Drugs Aging 2014;31:395-404.
17. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, et al: VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009;106:6152-6157.
18. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, et al: Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-3193.
19. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, et al: Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-437.
20. Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, et al: Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 2014;121:2432-2442.
21. Fassnacht-Riederle H, Becker M, Graf N, Michels S: Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 2014;252:1705-1709.
22. Heussen FM, Shao Q, Ouyang Y, Joussen AM, Muller B: Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2014;252:909-915.
23. Gregori NZ, Feuer W, Rosenfeld PJ: Novel method for analyzing Snellen visual acuity measurements. Retina 2010;30:1046-1050.
24. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-1433.
25. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, et al: Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434-457.